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Background: Currently, the dosage of tacrolimus used after transplantation is
based on the patient’s body weight. However, there is a low correlation between
body weight and body composition in kidney transplant recipients. In this study,
we evaluate the pharmacokinetics of tacrolimus according to body composition in
18 Korean kidney transplant recipients with stable graft function.
Methods: Body composition parameters were calculated using bioelectrical impe-
dance analysis. Pharmacokinetic proﬁles were determined 0, 1, 2, 3, and 4 hours
after treatment with tacrolimus and were compared between high- and low-level
median body composition groups. The values of C0, C1, C2, C3, and C4 were used in
determining an abbreviated area under the curve (AUC) for tacrolimus.
Results: The mean body mass index (BMI) and body composition values were as
follows: BMI, 24.3 kg/m2; lean mass, 49.8 kg; and fat mass, 17.4 kg. There were no
statistical differences in pharmacokinetic proﬁles between groups with different
BMIs. However, the C0 and C4 in the high-fat group were signiﬁcantly elevated
compared with those of the low-fat group (P¼0.024 and 0.031, respectively).
Furthermore, the C0, C2, C3, and C4 and the AUC were signiﬁcantly different
between the two lean mass groups (P¼0.007, 0.038, 0.047, 0.015, and 0.015,
respectively). Other variables, such as waist circumference and arm muscle
circumference, did not differentiate between the pharmacokinetic proﬁles of
tacrolimus.
Conclusion: Taken together, these data suggest that tacrolimus dose monitoring
based on body composition may provide adequate dosage leading to favorable
long-term outcomes.
& 2012. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).rean Society of Nephrology. P
ses/by-nc-nd/4.0/).
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).Introduction
Calcineurin inhibitors, such as cyclosporine and tacrolimus,
have a long history as immunosuppressants in the kidney
transplant ﬁeld [1,2]. The use of these inhibitors has improvedublished by Elsevier. This is an open access article under the CC BY-NC-
SS Han et al / Tacrolimus and body composition158short-term outcomes in kidney transplant patients [3], and
this improvement is primarily associated with fewer rejection
episodes [4]. However, these short-term improvements have
not led to parallel improvements in long-term outcomes and,
accordingly overall graft survival remains suboptimal. One of
reasons is chronic nephrotoxicity, which is the Achilles’ heel of
calcineurin inhibitors [5].
Calcineurin inhibitors are characterized by a narrow ther-
apeutic index and high inter-individual pharmacokinetic
variations. Owing to these challenging characteristics, other
regimens, such as using low doses of drugs or not using drugs,
have been introduced [6,7], but these regimens are not widely
accepted. Nonetheless, calcineurin inhibitors are still widely
used in clinical practice; therefore, it is important to deter-
mine the factors that affect drug concentration, to aid in the
prevention of chronic nephrotoxicity, as well as graft rejec-
tion. Several factors such as age, disease status, lipoprotein
concentrations, and genetic variations have been found in
pharmacokinetic studies [8].
After kidney transplantation, kidney recipients show a
change in body composition, including an increase in fat mass
and a decrease in lean mass [9]. The metabolic adverse events
of steroid and calcineurin inhibitor treatment can lead to
these changes and contribute to obesity [10]. Tacrolimus, a
calcineurin inhibitor, is highly lipophilic, and the partition
coefﬁcient of tacrolimus in n-octanol is 1000-fold greater than
in water. This lipophilicity is associated with the distribution
of tacrolimus mainly in fat-rich organs, such as adipose tissue,
liver, kidneys, and lymph nodes [11].
In this study, we hypothesized that the blood level and
distribution of tacrolimus would be inﬂuenced by the
patient’s body composition, and we aimed to verify this
hypothesis in Korean kidney transplant recipients.Methods
Patients
The institutional review board at the Seoul National Uni-
versity Hospital approved this study (no. H-1005-038-318).
Inclusion criteria were as follows: patients’ age Z20 years old;
transplanted at least 6 months previously; serum creatinine
concentration o2.0 mg/dL; change in serum creatinine level
o30% within 1 month; and receiving triple immunosuppres-
sive agents (steroid, mycophenolate mofetil, and tacrolimus).
The dosage of tacrolimus was adjusted to keep the morning
trough levels in the range of 5–10 ng/mL. We excluded patients
who had the following histories: multiorgan transplantation or
previous history of kidney transplantation; nephrotoxicity or
other serious adverse events induced by tacrolimus; acute
kidney injury within 1 month of the trial; taking other drugs
or foods known to affect tacrolimus pharmacokinetics (such as
antiepileptics, antimycotics, cholestyramine, and grape juice);
gastrointestinal disease (which can affect the absorption of
tacrolimus); current evidence of infection; and treatment
history for rejection or infection within 1 month of the trial.
Between November 2010 and August 2011, 18 patients were
enrolled in this study. All patients were of Korean origin. We
recorded clinical parameters, such as age at transplantation, sex,
and the cause of end-stage renal disease. Donor factors, includ-
ing age at transplantation, sex, and donor source (living relative,
living nonrelative, and cadaveric), were also evaluated.On the study day, each patient was admitted to the clinical
trials center in the fasting state. Next, blood samples were
obtained before the morning dose of tacrolimus (C0, serum
creatinine, blood urea nitrogen, hemoglobin, albumin, total
cholesterol, triglyceride, high- and low-density lipoprotein
cholesterols, and high-sensitivity C-reactive protein) and after
dosing (C1, C2, C3, C4). The whole-blood concentrations of
tacrolimus were determined by mass spectrometry. The area
under the curve (AUC) for the concentration versus time curve
of tacrolimus was calculated using the linear trapezoidal rule.
We used an abbreviated AUC (AUC0–4), which had provided
good correlation with the complete AUC in the monitoring of
tacrolimus [12–14]. The dose-adjusted concentrations and
AUC of tacrolimus were used throughout the study.
Body compositions, including lean mass (kg) and fat mass
(kg), were measured using bioelectrical impedance analysis
(BIA; Inbody 720; Biospace Company, Ltd., Seoul, Korea). We
also measured weight (kg), height (cm), and circumferences
(cm) of the waist, hip, arm, and arm muscles. BMI was
calculated as the weight divided by the square of the height (m).
Statistical analysis
All analyses and calculations were performed using SPSS
software (SPSS version 16.0, Chicago, IL, USA). Data are pre-
sented as the mean7standard deviation (SD) for continuous
variables and as a proportion for categorical variables. If the
distribution of the data was skewed, the median [interquartile
range (IQR)] was used. Correlations between BMI and body
composition (muscle mass and fat mass) were evaluated using
Pearson’s correlation method. We divided the patients into two
groups according to the median value for body composition.
Next, the blood concentrations and the AUCs of the two groups
were compared using the Mann-Whitney U test. A P value of
less than 0.05 was considered to be signiﬁcant.Results
Baseline characteristics
In this study, 18 kidney recipients were recruited from
Seoul National University Hospital. The baseline characteris-
tics of study subjects are described in Table 1. The mean age
of testing was 44 years. Of the 18 patients, 7 had received
grafts from deceased donors. There were no ABO-incompa-
tible transplantations. All of the participants had stable graft
function, and serum creatinine concentrations ranged from
0.91 mg/dL to 1.82 mg/dL. There was no evidence of possible
infectious or inﬂammatory diseases. Furthermore, 15 patients
had high-sensitivity C-reactive protein concentrations of less
than 0.1 mg/dL, whereas the other three patients did not. The
causes of patients’ end-stage renal disease included diabetes
mellitus (ﬁve), glomerulonephritis (four), autosomal domi-
nant polycystic kidney disease, drug-related disease, and
kidney donor. Of all of the patients, six recipients did not
know the original cause of end-stage renal disease.
Body composition parameters
All of the patients underwent the BIA for assessing body
compositions (Table 2). The mean BMI was 24.3 kg/m2. Of all
total patients, a BMI of more than 25.0 kg/m2 was measured in
Table 2. Body composition parameters estimated by bioelectrical impedance analysis
Lean mass Fat mass Total (n¼18)
High level group
(n¼9)
Low level group
(n¼9)
High level group
(n¼9)
Low level group
(n¼9)
Body weight (kg) 77.377.87 57.276.01 76.179.07 58.377.96 67.2712.37
Height (cm) 172.174.81 159.675.10 168.978.25 162.876.98 165.878.05
Body mass index (kg/m2) 26.071.97 22.573.02 26.671.72 22.072.15 24.373.06
Lean mass (kg) 57.276.03 42.574.40 55.278.10 44.476.81 49.879.15
Proportion of lean mass (%) 74.173.21 74.575.88 72.474.02 76.274.56 74.374.60
Fat mass (kg) 20.173.50 14.774.45 20.973.27 13.873.04 17.474.77
Proportion of fat mass (%) 26.073.21 25.575.93 27.674.01 23.874.59 25.774.63
Waist circumference (cm) 90.175.88 81.875.02 89.975.97 82.075.32 85.976.82
Hip circumference (cm) 97.774.87 90.974.83 98.075.00 90.674.10 94.375.86
Waist-to-hip ratio 0.9270.033 0.9070.042 0.9270.033 0.9170.044 0.9170.038
Arm circumference (cm) 24.671.61 21.571.80 24.671.62 21.671.85 23.172.29
Arm muscle circumference (cm) 31.272.04 27.672.32 31.671.80 27.371.80 29.472.82
Table 1. Baseline characteristics of the study participants
Lean mass Fat mass Total (n¼18)
High level group
(n¼9)
Low level group
(n¼9)
High level group
(n¼9)
Low level group
(n¼9)
Age (y) 45711.1 43713.4 44713.7 44711.0 44712.0
Recipient’s male sex (%) 100.0 55.6 88.9 66.7 77.8
Deceased donor (%) 55.6 22.2 33.3 44.4 38.9
Donor’s age (y) 3177.3 3379.3 3578.6 2976.8 3278.2
Donor’s male sex (%) 75.0 55.6 50.0 77.8 64.7
HLA mismatching 371.8 371.9 371.8 371.9 371.8
Serum biochemical marker
Creatinine (mg/dL) 1.370.17 1.270.29 1.370.17 1.270.29 1.270.23
Glucose (mg/dL) 107718.9 120783.4 105720.0 121782.9 113759.1
Bilirubin (mg/dL) 1.070.41 0.770.24 1.070.43 0.770.24 0.970.36
Total cholesterol (mg/dL) 168737.6 164728.0 175725.8 158737.0 166732.2
Triglyceride (mg/dL) 174753.8 140742.9 168744.8 146755.9 157750.4
HDL cholesterol (mg/dL) 4679.2 51715.1 4878.8 48715.9 48712.5
LDL cholesterol (mg/dL) 101736.0 95725.3 105730.1 90730.4 98730.3
High-sensitivity CRP (mg/dL)n 0.01 (0.01–0.08) 0.06 (0.01–0.08) 0.01 (0.01–0.04) 0.06 (0.01–1.00) 0.01 (0.01–0.07)
From operation to test (mo)n 40 (10–57) 56 (34–100) 26 (10–61) 56 (43–99) 46 (16–74)
n Data are expressed as the median (interquartile range) when the distribution of data was skewed.
CRP, C-reactive protein; HDL, high-density lipoprotein; HLA, human leukocyte antigen; LDL, low-density lipoprotein.
Kidney Res Clin Pract 31 (2012) 157–162 159eight patients, and a BMI greater than 30.0 kg/m2 was mea-
sured in one patient. We analyzed the correlation between
BMI and body composition parameters such as lean mass and
fat mass and found a positive correlation (Po0.05). Among
those parameters, fat mass had a stronger correlation with
BMI than did lean mass (R¼0.875 and 0.706, respectively).
Body weight had signiﬁcant correlations with body composi-
tion parameters except waist-to-hip ratio. Correlation of body
weight with fat mass was weaker than correlation with lean
mass (R¼0.782 and 0.947, respectively). Waist circumference
had a stronger correlation with fat mass (R¼0.757) than lean
mass (R¼0.613). However, arm muscle circumference was
better correlated with lean mass (R¼0.917) than with fat mass
(R¼0.619).
Tacrolimus concentration according to body composition
We evaluated the blood concentrations of tacrolimus after
dividing the patients into two groups according to median
body-composition values. When considering BMI, the tacroli-
mus concentrations from 0 to 4 hours were not different
between the high and the low level groups (P40.05 allcomparisons). However, the concentrations at 0 and 4 hours
were different between the groups with the high and low of
fat-mass values (C0, P¼0.024; C4, P¼0.031). This is shown in
Fig. 1. In the lean mass analysis, the concentrations at all
times except 1 hour (C1) were different (C0, P¼0.007; C2,
P¼0.038; C3, P¼0.047; C4, P¼0.015). This is shown in Fig. 1.
However, tacrolimus concentrations did not signiﬁcantly vary
with waist and arm muscle circumference, unlike with lean
and fat mass values [waist circumference; all P values were
greater than 0.05; arm muscle circumference, all P values
were greater than 0.05 except C0 (P¼0.031)].
The differences between the AUC of the body composition
groups are shown in Table 3. The AUC was signiﬁcantly
different according to lean-mass value but not between the
groups classiﬁed using other parameters.Discussion
The present study evaluated the relationship between the
pharmacokinetic proﬁles of tacrolimus and body composition
parameters. The results showed that BMI did not differentiate
SS Han et al / Tacrolimus and body composition160between the tacrolimus concentrations, but the lean mass and
fat mass did differentiate between tacrolimus concentrations.
Furthermore, the AUC for tacrolimus was different only when
the patients were classiﬁed according to lean-mass group.
These data may suggest that the body composition should be
considered in tacrolimus dose monitoring.
Tacrolimus is a representative immunosuppressive drug
that has emerged as a valuable therapeutic alternative to
cyclosporine after solid organ transplantation [15]. Tacroli-
mus not only has a positive effect on short-term graft function
but may also have a negative effect on long-term function.
When tacrolimus is maintained at high levels in the blood,
several negative effects are observed, such as nephrotoxicity,
neurotoxicity, diabetes, gastrointestinal disturbance, hyper-
tension, and infections [15,16]. Because of these toxicities, the
tacrolimus level should be adjusted and maintained within a
narrow therapeutic window. However, there is considerable
inter- and intraindividual variability in the pharmacokinetic
proﬁle of tacrolimus, and the adjustment of tacrolimus levelsTable 3. Area under the concentration–time curve for tacrolimus in th
Parameter High level group (n¼9)
Body mass index 20.1 (14.35–24.59)
Lean mass 21.2 (17.34–25.93)
Fat mass 20.1 (17.34–24.59)
Waist 18.5 (14.06–24.15)
Hip 19.3 (17.19–23.62)
Waist-to-hip ratio 18.4 (11.71–23.59)
Arm circumference 20.1 (17.34–24.59)
Arm muscle circumference 20.1 (14.35–24.59)
Figure 1. Concentrations of tacrolimus after classifying patients
into groups according to median fat-mass (A) and lean-mass (B).
The tacrolimus concentrations of the two groups are compared using
the Mann-Whitney U test. *Po0.05.is not easy. Thus, factors related to the pharmacokinetics of
tacrolimus have been heavily studied. Tacrolimus is a highly
lipophilic drug [17], and the distribution of tacrolimus is
predominantly in the fat-rich organs, such as adipose tissue.
However, studies on the relationship between tacrolimus
levels and body composition have not been conducted. The
current study is the ﬁrst to demonstrate that body composi-
tion is one of several factors that should be considered in
determining the tacrolimus level.
Previously, some studies have shown that being overweight
is a risk factor for high blood concentrations of calcineurin
inhibitors [18–21]. Although their study was not designed to
measure pharmacokinetics, Rodrigo and colleagues [18]
showed that a transplant recipient group with a high BMI
was associated with tacrolimus levels higher than 15 ng/mL.
With respect to pharmacokinetic design, cyclosporine has
been more intensively studied with respect to body weight.
In most studies, patients with a higher BMI have been found to
require less cyclosporine to maintain therapeutic trough levels
[19–21]. However, other studies have found the opposite
results [22]. The current study showed that BMI level is not
related to tacrolimus concentrations. The variable results in
previous studies may have arisen from the shortcoming of
measuring BMI. Although BMI is used for indicating obesity,
BMI does not differentiate lean mass from fat tissue [23]. Our
previous research has already shown that there is only a weak
correlation between BMI and lean mass [24], and the correla-
tion was lesser in the disease groups. Furthermore, some
studies did not ﬁnd a negative correlation between BMI and
mortality, and this ﬁnding has been termed the ‘‘obesity
paradox.’’ This paradoxical phenomenon is observed mainly
in disease states and the elderly [25]. Transplant recipients
also have different body compositions, owing to immunosup-
pressive agents [26]; therefore, BMI may not be a perfect
substitute for fat mass or other body composition parameters.
Therefore, the effect of BMI on pharmacokinetics in transplant
recipients could vary according to their body composition.
In the current study, fat mass was correlated with the
concentrations of tacrolimus at certain time points (C0 and C4)
of tacrolimus. Because tacrolimus is highly lipophilic, an
individual’s fat mass composition may affect the pharmaco-
kinetics of this drug. In other words, the factor determining
the tacrolimus level is the proportion of fat mass, not the BMI
or body weight. Lean mass was also shown to be correlated
with the concentrations of tacrolimus at certain time points
(C0, C2, C3, and C4) and the AUC of tacrolimus. The reason for
this correlation is not clear, but one possibility is a difference
in liver volume. Patients with high lean-mass values have
larger liver volumes [27], and tacrolimus accumulates in the
liver tissue. These relationships may affect the tacrolimus
level. Evidence from some studies suggests that lean mass is ae high and the low level groups of body composition parameters
Low level group (n¼9) P
17.0 (11.07–19.05) 0.200
12.3 (10.86–18.45) 0.015
12.3 (10.98–19.05) 0.122
17.5 (11.07–22.07) 0.453
14.9 (10.87–20.96) 0.237
17.5 (11.07–22.82) 0.691
12.3 (10.86–19.05) 0.070
17.0 (11.07–19.05) 0.200
Kidney Res Clin Pract 31 (2012) 157–162 161better predictor of the appropriate drug dosage than total
body weight, although the mechanism underlying this is not
fully established [28]. However, calculating dosage on the
basis of lean mass is known to be more accurate for drugs
with weak or moderate lipophilicity [29]. This issue should be
further delineated in future studies.
Although our results are informative, this study has some
limitations. First, we did not check variations in genes that
might affect the pharmacokinetics of tacrolimus, such as
cytochrome P-450 gene [30]. Second, we used the abbreviated
AUC (AUC0-4) instead of the complete AUC. However, the
abbreviated AUC has been identiﬁed to adequately monitor
and guide tacrolimus dosing and may be quicker and more
inexpensive in clinical practice than the complete AUC. Third,
the number of study participants is relatively small, although
the study is designed for pharmacokinetics. Therefore, the
statistical power in the correlation analysis may not be strong
enough to detect statistical signiﬁcance.
In summary, body composition parameters were found to
be associated with the blood level of tacrolimus in kidney-
transplant recipients. This trend was stronger when consider-
ing lean mass than other body composition parameters. The
BMI was not associated with the blood level or the AUC of
tacrolimus. Body weight is commonly used to calculate
tacrolimus dosage. However, total body-weight and BMI
values cannot be easily substituted for lean-mass and fat-
mass values in kidney-transplant recipients. Measuring body
composition can more precisely determine tacrolimus levels
in kidney transplant recipients. In the future, well-designed
research and intervention studies will be required to identify
the importance of these correlations.Conﬂict of interest
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